« Return to News | Drug Sponsors | R&D Trends

Bristol-Myers Squibb to acquire Inhibitex

Monday, January 9, 2012 03:59 PM

Bristol-Myers Squibb has agreed to acquire Inhibitex, a biopharmaceutical company, for $26 per share, or approximately $2.5 billion, in cash.

Inhibitex, most known for its focus on drugs that prevent and treat hepatitis C, has given Bristol-Myers Squibb (BMS) INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. BMS will also acquire two other products in phase II development (FV-100 and Aurexis) and several other fully developed products that prevent and treat serious infection diseases.

"The addition of Inhibitex's nucleotide polymerase inhibitor to our own promising portfolio, which includes other direct-acting antivirals, brings additional options to develop all-oral regimens with better cure rates, shorter duration of therapy and lower toxicity than the current standard of care,” said Elliott Sigal, M.D., Ph.D., chief scientific officer for BMS.

BMS announced a cash tender offer to purchase all outstanding shares of Inhibitex’s common stock for $26 per share.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.